SCHEMBL6924877

SCHEMBL6924877

Fc1ccc(-c2c[nH]c(-c3ccnc(N4CCN(CC5CC5)CC4)c3)n2)cc1F

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIK3C3 Q8NEB9 1/20 0.38
PRKD1 Q15139 1/20 0.38
KCNH2 Q12809 4/20 0.37
RPS6KB1 P23443 1/20 0.37
AKT1 P31749 1/20 0.37
CYP17A1 P05093 1/20 0.36
CYP21A2 P08686 1/20 0.36
CYP11B1 P15538 1/20 0.36
TRPV3 Q8NET8 1/20 0.36
LRRK2 Q5S007 2/20 0.35
CASP1 P29466 1/20 0.35
CASP4 P49662 1/20 0.35
CASP5 P51878 1/20 0.35
TRPA1 O75762 1/20 0.35
RET P07949 1/20 0.34
PARP1 P09874 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6922166 0.92 PIK3C3 (0.40) PIK3C3PRKD1CYP17A1CYP21A2CYP11B1
SCHEMBL6926804 0.91 TRPA1 (0.39) PRKD1KCNH2CYP17A1CYP21A2CYP11B1
SCHEMBL6924980 0.90 DRD2 (0.42) PIK3C3KCNH2RPS6KB1AKT1
SCHEMBL6927160 0.89 DRD2 (0.43) PIK3C3PRKD1LRRK2CASP1CASP4
SCHEMBL6927205 0.87 KCNH2 (0.40) PIK3C3KCNH2CYP11B1TRPV3LRRK2
SCHEMBL6927463 0.87 KDM4E (0.40) PRKD1RPS6KB1AKT1LRRK2
SCHEMBL6923588 0.86 PIK3C3 (0.40) PIK3C3PRKD1LRRK2CASP1CASP4
SCHEMBL6928029 0.85 SMG1 (0.43) PIK3C3PRKD1LRRK2
SCHEMBL6921703 0.85 LRRK2 (0.43) PIK3C3KCNH2RPS6KB1AKT1TRPV3
SCHEMBL6925150 0.85 WNT1 (0.42) PIK3C3PRKD1KCNH2TRPV3LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6355635-B1 IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY PFIZER INC. 2002-03-12 US claimed
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 US claimed
WO-2000066578-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY PFIZER PRODUCTS INC. (US) 2000-11-09 WO claimed
US-6514966-B2 Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine PFIZER INC. 2003-02-04 US disclosed
US-6355635-B1 IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY PFIZER INC. 2002-03-12 US disclosed
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 US disclosed
WO-2000066578-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY PFIZER PRODUCTS INC. (US) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039277-A1 Compounds for the treatment of obesity NPY1R, NPY4R, NPY2R PIK3C3 4567/4885PRKD1 3834/4885KCNH2 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.